179 related articles for article (PubMed ID: 37193249)
41. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.
Xiong A; Wang J; Zhou C
Front Oncol; 2021; 11():757993. PubMed ID: 34900707
[TBL] [Abstract][Full Text] [Related]
44. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Yang Q; Chen M; Gu J; Niu K; Zhao X; Zheng L; Xu Z; Yu Y; Li F; Meng L; Chen Z; Zhuo W; Zhang L; Sun J
Front Immunol; 2021; 12():665133. PubMed ID: 33936103
[TBL] [Abstract][Full Text] [Related]
45. High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
Frigola J; Carbonell C; Irazno P; Pardo N; Callejo A; Cedres S; Martinez-Marti A; Navarro A; Soleda M; Jimenez J; Hernandez-Losa J; Vivancos A; Felip E; Amat R
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35477861
[TBL] [Abstract][Full Text] [Related]
46. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Sun Y; Yang Q; Shen J; Wei T; Shen W; Zhang N; Luo P; Zhang J
Front Cell Dev Biol; 2021; 9():745859. PubMed ID: 34660603
[No Abstract] [Full Text] [Related]
47. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
48. Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy.
Li C; Pan J; Luo J; Chen X
BMC Pulm Med; 2021 Nov; 21(1):389. PubMed ID: 34844602
[TBL] [Abstract][Full Text] [Related]
49. Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer.
Sun D; Tian L; Zhu Y; Wo Y; Liu Q; Liu S; Li H; Hou H
Mol Med; 2020 Aug; 26(1):78. PubMed ID: 32791957
[TBL] [Abstract][Full Text] [Related]
50. Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma.
Xiang S; Li J; Shen J; Zhao Y; Wu X; Li M; Yang X; Kaboli PJ; Du F; Zheng Y; Wen Q; Cho CH; Yi T; Xiao Z
Front Immunol; 2021; 12():653836. PubMed ID: 33897701
[No Abstract] [Full Text] [Related]
51. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
52. Association of
Cui Y; Zhang P; Liang X; Xu J; Liu X; Wu Y; Zhang J; Wang W; Zhang F; Guo R
Am J Cancer Res; 2022; 12(4):1766-1783. PubMed ID: 35530271
[TBL] [Abstract][Full Text] [Related]
53. Guanylate binding protein 5 accelerates gastric cancer progression via the
Cao FY; Wang CH; Li X; Ma MZ; Tao GC; Yang C; Li K; He XB; Tong SL; Zhao QC; Su S; Song D; Zheng YB
Am J Cancer Res; 2023; 13(4):1310-1328. PubMed ID: 37168340
[TBL] [Abstract][Full Text] [Related]
54. Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.
Ding H; Xin W; Tong Y; Sun J; Xu G; Ye Z; Rao Y
PLoS One; 2020; 15(9):e0238536. PubMed ID: 32877435
[TBL] [Abstract][Full Text] [Related]
55. Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients.
Song P; Yang D; Wang H; Cui X; Si X; Zhang X; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1621-1632. PubMed ID: 32329229
[TBL] [Abstract][Full Text] [Related]
56. Clinicopathological and predictive value of MAIT cells in non-small cell lung cancer for immunotherapy.
Shi L; Lu J; Zhong D; Song M; Liu J; You W; Li WH; Lin L; Shi D; Chen Y
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657812
[TBL] [Abstract][Full Text] [Related]
57. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
58. Clinical Significance and the Role of Guanylate-Binding Protein 5 in Oral Squamous Cell Carcinoma.
Liu PF; Shu CW; Lee CH; Sie HC; Liou HH; Cheng JT; Ger LP; Chen CL; Chen CC; Chen CF
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439200
[TBL] [Abstract][Full Text] [Related]
59. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
[TBL] [Abstract][Full Text] [Related]
60. Expression of Microtubule-Associated Proteins in Relation to Prognosis and Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.
Luo J; Hu Q; Gou M; Liu X; Qin Y; Zhu J; Cai C; Tian T; Tu Z; Du Y; Deng H
Front Oncol; 2021; 11():680402. PubMed ID: 34660263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]